| Abstract |
Both diet and medications are useful in the treatment of the obese patient. Weight loss of about 10% below baseline can be achieved with both, and there is no evidence that the composition of the diet, by itself, has any influence on weight loss. Presently only 1 drug is approved for long-term treatment of overweight patients, and its effectiveness is limited to palliation of the chronic disease of obesity. Combinations of medications and antidiabetic drugs that produce weight loss are being evaluated. |
| Authors | George A Bray, Donna H Ryan |
| Journal | The Psychiatric clinics of North America
(Psychiatr Clin North Am)
Vol. 34
Issue 4
Pg. 871-80
(Dec 2011)
ISSN: 1558-3147 [Electronic] United States |
| PMID | 22098810
(Publication Type: Journal Article)
|
| Chemical References |
- Anti-Obesity Agents
- Antidepressive Agents, Second-Generation
- Drug Combinations
- Hypoglycemic Agents
- Islet Amyloid Polypeptide
- Lactones
- Narcotic Antagonists
- Peptides
- Sympathomimetics
- Venoms
- Bupropion
- Topiramate
- Fructose
- Naltrexone
- Metformin
- Orlistat
- Exenatide
- pramlintide
|
| Topics |
- Adolescent
- Adult
- Anti-Obesity Agents
(adverse effects, pharmacology, therapeutic use)
- Antidepressive Agents, Second-Generation
(therapeutic use)
- Body Weight
(drug effects)
- Bupropion
(therapeutic use)
- Child
- Drug Approval
- Drug Combinations
- Energy Intake
(drug effects)
- Exenatide
- Female
- Fructose
(analogs & derivatives, therapeutic use)
- Humans
- Hypoglycemic Agents
(pharmacology, therapeutic use)
- Islet Amyloid Polypeptide
(therapeutic use)
- Lactones
(pharmacology, therapeutic use)
- Male
- Metformin
(therapeutic use)
- Naltrexone
(therapeutic use)
- Narcotic Antagonists
(therapeutic use)
- Obesity
(drug therapy, metabolism)
- Orlistat
- Patient Compliance
- Peptides
(therapeutic use)
- Randomized Controlled Trials as Topic
- Sympathomimetics
(adverse effects, therapeutic use)
- Topiramate
- United States
- United States Food and Drug Administration
- Venoms
(therapeutic use)
|
